Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects

Xenobiotica

Volumn 37, Issue 3, 2007, Pages 315-327

  Hu, Y F ^a,b   Tu, J H ^a   Tan, Z R ^a   Liu, Z Q ^b   Zhou, G ^a   He, J ^a   Wang, D ^a   Zhou, H H ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

Cyclosporine; CYP3A4; Pharmacokinetics; Polymorphisms

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; CYTOCHROME P450 3A4; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; IMMUNOSUPPRESSIVE AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; ADOLESCENT; ASIAN; GENETICS; METABOLISM;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 33947379735     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250601149206     Document Type: Article

References (30)

1. Aoyama T, Yamano S, Waxman DJ, et al. 1989. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. Journal of Biological Chemistry 264:10388-10395.
2. Blin N, Stafford DW. 1976. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Research 3:2303-2308.
3. 2 concentrations. Transplantation Proceedings 36(Suppl 2S):437S-41S.
4. Clase CM, Mahalati K, Kiberd BA, et al. 2002. Adequate early cyclosporine exposure is critical to prevent renal allograft rejection: Patients monitored by absorption profiling. American Journal of Transplantation 2:789-795.
5. Dai D, Tang J, Rose R, et al. 2001. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. Journal of Pharmacology and Experimental Therapeutics 299:825-831.
6. Evans WE, McLeod HL. 2003. Pharmacogenomics - drug disposition, drug targets and side effects. New England Journal of Medicine 348:538-549.
7. Evans WE, Relling MV. 1999. Pharmacogenetics: Translating functional genomics into rational therapeutics. Science 286:487-491.
8. Feng HJ, Huang SL, Wang W, Zhou HH. 1998. The induction effect of refampicin on activity of mephenytoin 4′-hydroxylase related to M1 mutation of CYP2C19 and gene dose. British Journal of Clinical Pharmacology 45:27-29.
9. Fukushima-Uesaka H, Saito Y, Watanabe H, et al. 2004. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Human Mutation 26:100-108.
10. Guengerich FP. 1999. Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annual Review of Pharmacology and Toxicology 38:389-430.
11. Hesselink DA, van Schaik RH, van der Heiden IP, et al. 2003. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineur ininhibitors cyclosporine and tacrolimus. Clinical Pharmacology and Therapeutics 74:245-254.
12. Hsieh KP, Lin YY, Cheng CL, et al. 2001. Novel mutations of CYP3A4 in Chinese. Drug Metabolism and Disposition 29:268.
13. Hu YF, He J, Chen GL, et al. 2005. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chem Acta 353:187-192.
14. Hunt CM, Westerkam WR, Stave GM. 1992. Effect of age and gender on the activity o human hepatic CYP3A. Biochemical Pharmacology 44:275-283.
15. Kelly P, Kahan BD. 2002. Review: Metabolism of immunosuppressant drugs. Current Drug Metabolism 3:275-287.
16. Kronbach T, Fischer V, Meyer UA. 1988. Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine metabolizing enzyme explains interactions of cyclosporine with other drugs. Clinical Pharmacology and Therapeutics 43:630-635.
17. Lown KS, Kolars JC, Thummel KE, et al. 1994. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metabolism and Disposition 22:947-955.
18. Mahalati K, Belitsky P, Sketris I, West K, Panek R. 1999. Neoral monitoring by simplified sparse sampling area under the concentration-time curve. Transplantation 68:55-62.
19. Min DI, Ellingrod VL. 2003. Association of the CYP3A4*1B 5′-flanking region polymorphism with cyclosporine pharmacokinetics in the healthy subjects. Therapeutic Drug Monitoring 25:305-309.
20. Ozdemir V, Kalowa W, Tang BK, et al. 2000, Evaluation of the genetic component of variability in CYP3A4 activity: A repeated drug administration method. Pharmacogenetics 10:373-388.
21. Pichard L, Fabre I, Fabre G, et al. 1990. Cyclosporin A drug interaction. Screening for inducers and inhibitors of cytochrome P450 (cyclsoporin oxidase) in primary culture of human hepatocytes and in liver microsomes. Drug Metabolism and Disposition 18:595-606.
22. Taylor PJ, Jones CE, Martin PT, et al. 1998. Microscale high-performance liquid chromatography-electrospray tandem mass spectrometry assay for cyclosporin A in blood. Journal of Chromatology B. Biomedical Sciences and Applications 705:289-294.
23. Thummel KE, Wilkinson GR. 1998. In vitro and in vivo drug interactions involving human CYP3A. Annual Review of Pharmacology and Toxicology 39:1-17.
24. von Ahsen N, Richter M, Group C, et al. 2001. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporine A trough concentration or rejection incidence in stable renal transplant recipients. Clinical Chemistry 47:1048-1052.
25. Wang JH, Liu ZQ, Wang W, Cheng XP, Shu Y, He N, et al. 2001. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clinical Pharmacology and Therapeutics 70:42-47.
26. Watkins PB, Wrighton SA, Maurel P. et al. 1985. Identification of an inducible from cytochrome P-450 in human liver. Proceedings of the National Academy of Sciences, USA 82:6310-6314.
27. Wójcikowski J, Pichard-Garcia L, Maurel P, Daniel WA. 2002. Perazine as a potent inhibitor of human CYP1A2 but not CYP3A4. Polish Journal of Pharmacology 54:407-410.
28. Wrighton SA, Ring BJ, Watkins PB, Vandenbranden M. 1989. Identification of a polymorphically expressed member of the human cytochrome P-450 family. Molecular Pharmacology 36:97-105.
29. Xiao ZS, Goldstein JA, Xie HG, et al. 1997. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. Journal of Pharmacology and Experimental Therapeutics 281:604-609.
30. Zhu B, Liu ZQ, Chen GL, et al. 2003. The distribution and gender difference of CYP3A activity in Chinese subjects. British Journal of Clinical Pharmacology 55:264-269.